ロード中...
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis
Fibroblast growth factor (FGF)19, an endocrine hormone produced in the gut, acts in the liver to control bile acid synthesis. NGM282, an engineered FGF19 analog, is currently in clinical development for treating nonalcoholic steatohepatitis. However, the molecular mechanisms that integrate FGF19 wit...
保存先:
| 出版年: | J Lipid Res |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The American Society for Biochemistry and Molecular Biology
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6399511/ https://ncbi.nlm.nih.gov/pubmed/30679232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M089961 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|